[Pharmacology of a 1H-1, 2, 4-triazolyl benzophenone derivative (450191-S), a new sleep-inducer (III). Behavioral study on interactions of 450191-S and other drugs in mice].
Interactions between 450191-S and other representative drugs which might be clinically used with 450191-S were behaviorally investigated in mice, and compared with the cases of nitrazepam, estazolam and triazolam. The potencies of 450191-S and nitrazepam in preventing pentetrazol convulsions were markedly decreased by aminopyrine, whereas that of estazolam was remarkably increased by phenytoin. Administration of nitrazepam with other drugs, except aminopyrine, or of estazolam together with haloperidol exhibited an anticonvulsive pattern different from the case of dosing with either drug alone. Only the effect of triazolam was not influenced by any drugs used. The potency of haloperidol against apomorphine-induced climbing behavior was significantly reduced by nitrazepam, and the pattern of the haloperidol effect was changed by treatment together with 450191-S or estazolam. However, triazolam had no influence on the effect of haloperidol. The antagonistic activity of imipramine to reserpine-induced hypothermia was slightly decreased by 450191-S, estazolam and triazolam, but little affected by nitrazepam. In the protection from maximal electroshock convulsions (MEC), the potency of phenytoin was significantly decreased by 450191-S and triazolam. Moreover, the anti-MES pattern of phenytoin was altered by nitrazepam. Estazolam exerted no significant influence on the effect of phenytoin. Analgesic activities of morphine and/or aminopyrine were potentiated by pretreatment with sleep-inducers, but not 450191-S. Thus, judging from the potency and stability of the anti-pentetrazol effect, 450191-S seems to be inferior to triazolam, but superior to nitrazepam and estazolam. Also, 450191-S may be differentiated from other sleep-inducers by the fact that only 450191-S did not potentiate the analgesic activities of morphine and aminopyrine.
D000632:Aminopyrine / Q000008:administration & dosage; D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D001058:Apomorphine / Q000008:administration & dosage; D001522:Behavior, Animal / Q000187:drug effects*; D001569:Benzodiazepines; D002490:Central Nervous System / Q000187:drug effects*; D002491:Central Nervous System Agents / Q000008:administration & dosage*; D006220:Haloperidol / Q000008:administration & dosage; D006993:Hypnotics and Sedatives / Q000008:administration & dosage*; D007099:Imipramine / Q000008:administration & dosage; D008297:Male; D051379:Mice; D010433:Pentylenetetrazole / Q000008:administration & dosage; D010672:Phenytoin / Q000008:administration & dosage; D012110:Reserpine / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage*
D014151:Anti-Anxiety Agents; D002491:Central Nervous System Agents; D006993:Hypnotics and Sedatives; D014230:Triazoles; D000632:Aminopyrine; D001569:Benzodiazepines; D010672:Phenytoin; D012110:Reserpine; C041075:rilmazafone; D006220:Haloperidol; D001058:Apomorphine; D007099:Imipramine; D010433:Pentylenetetrazole